Document is current
Any future updates will be listed below
-
Authors
Abrahamsen, Bo https://orcid.org/0000-0002-2730-6080
Smith, Christopher D. https://orcid.org/0000-0002-1909-9245
Minisola, Salvatore https://orcid.org/0000-0001-6525-0439
-
Funding
Funding for this research was provided by:
Kyowa Kirin International
- License Information
-
More Information
Article History
Received: 11 January 2021
Accepted: 19 March 2021
First Online: 5 April 2021
Declarations
:
: BA: Consulting and speakers fees Amgen, UCB, Kyowa-Kirin International. Institutional research contracts UCB and Novartis. CDS: None. SM: Served as speaker for Abiogen, Amgen, Bruno Farmaceutici, Diasorin, Eli Lilly, Shire, Sandoz, Takeda. He also served on advisory boards of Abiogen, Kyowa Kirin, Pfizer, UCB.
: Not required under Danish law. Data were maintained by Statistics Denmark (study reference 707,907) and only accessed by the researchers using VPN access to Statistics Denmark servers, with only aggregated statistical tables being allowed to be moved out from the server. The study was approved by the institutional data privacy board for the University of Southern Denmark (10.936) as authorized by the Data Protection Agency and conducted through the Open Patient Data Explorative Network (ref OP 1085).
